Tuesday, April 14, 2015
New Biomarker for Uterine Cancer
Researchers at Uppsala University have discovered a new biomarker that helps identify women with uterine cancer who have a high risk of recurrence. Uterine cancer is the most common form of gynecologic cancer in the United States. The treatment usually includes removal of the uterus, and often administering chemotherapy, if recurrence is predicted.
This study focuses on the amount of a specific protein, ASRGL1, present in tumor cells in the cancer. ASRGL1 is an enzyme that exists normally in cells of the uterus. The study suggests that patients who entirely lost or had low amounts of ASRGL1 in their tumor cells were more likely to relapse than patients who had normal levels of ASRGL1 in their tumor cells.
This biomarker is important because it could become a diagnostic tool to help identify patients who are likely to relapse. Therefore, this allows for more initial extensive treatment to try to prevent the relapse from occurring.
My Article
Related Article
Labels:
biomarker,
cancer,
proteins,
uterine cancer
Subscribe to:
Post Comments (Atom)
This study could be very helpful in determining the treatment of patients with this type of cancer. It would be interesting to see if a woman is predicted to have a low risk for recurrence, if a another form of treatment besides the removal of their uterus or chemotherapy could be replaced by a less invasive form of treatment.
ReplyDelete